Haku’s lymphoma was intially diagnosed in November of 2022. His initial remission ended this past January, and his restarted CHOP protocol failed shortly thereafter. His third, different treatment was ineffective, and, as of yesterday, we’re trying a fourth: Tanovea. It has a 40-50% chance of helping in stage IIIa, and we hope it’ll give him more happy days.
It’s clear, though, as we approach the end of this journey, that every additional good day is a gift, for him and us.
